buffer without detergent  (Bio-Rad)

Journal: Scandinavian journal of clinical and laboratory investigation

Article Title: Endogenous anti-streptavidin antibodies causing erroneous laboratory results more common than anticipated.

doi: 10.1080/00365513.2020.1858493

Figure Lengend Snippet: Figure 3. Individual patient concentrations from the 34 samples with confirmed endogenous anti-streptavidin antibodies. Both the Roche method and alternative methods were used in 29 TSH, 30 FT4 and 24 FT3, 15 TRAb and five Anti-TPO samples. Concentrations above and below the measuring limits were given the meas- uring limit values. TSH, FT4 and FT3 values obtained by the Roche method were adjusted for method dependent differences according to the equations listed in Table 1. (A) Median TSH in the 29 samples was 1.03 mIU/L (range 0.07–64.20) with the Roche method and 1.84 mIU/L (range <0.03 to >100) with the DELFIA method. (B) Median FT4 in the 30 samples was 30.8 pmol/L (range 13.4 to >78.8) with the Roche method and 13.9 pmol/L (range 6.2–26.0) with the DELFIA method. (C) Median FT3 in the 24 samples was 10.5 pmol/L (range 6.5–18.2) with the Roche method and 6.0 pmol/L (range 3.5–9.6) with the alternative methods. (D, E) Fifteen TRab results and five Anti-TPO results analysed to be positive with the Roche method, were negative when analysed with alternative methods. RR: ref- erence range; results above or below the measuring limit.

Article Snippet: Dissociation enhanced lanthanide fluorescence immunoassay (DELFIA, Perkin Elmer) was used for the determination of serum TSH (reference range, RR: 0.5–3.6 mIU/L), FT4 (RR: 8.0–21.0 pmol/L) and until February 2016 for determination of FT3 (RR: 3.5–8.3 pmol/L).

Techniques:

Journal: Scandinavian journal of clinical and laboratory investigation

Article Title: Endogenous anti-streptavidin antibodies causing erroneous laboratory results more common than anticipated.

doi: 10.1080/00365513.2020.1858493

Figure Lengend Snippet: Figure 4. Comparison of results from the Roche method and alternative methods in the 42-sample set sent to Roche Diagnostics for further investigation and in the 51- sample set not investigated for the source of interference. Concentrations above and below the detection limit were given the detection limit values. Values obtained by the Roche method were adjusted for method dependent differences according to the equations listed in Table 1. Median, 25 and 75 percentiles and 95% confidence intervals are shown. (A) TSH. 42-sample set: 35 TSH samples measured with Roche and DELFIA method, median TSH Roche concentration was 1.03 mIU/L (range 0.07–64.20), median TSH DELFIA concentration was 1.86 mIU/L (range <0.03 to >100). 51-sample set: 44 TSH samples measured with both methods, median Roche concentration was 1.12 (range 0.08–78.46), median DELFIA concentration was 1.86 mIU/L (range 0.32–10.70). Y-axis uses logarithmic scale. (B) FT4. 42-sample-set: 37 FT4 samples measured with Roche and DELFIA method, median FT4 Roche concentration was 28.8pmol/L (range 5.7 to >78.8), median FT4 DELFIA concentration was 14.1pmol/L (range 6.2–26.0). 51- sample set: 47 FT4 measured with both methods, median FT4 Roche concentration was 28.0pmol/L (range 14.9 to >78.8), median FT4 DELFIA concentration was 14.6pmol/L (range 10.6–33.4). (C) FT3. 42-sample set: 25 FT3 samples measured with Roche and alternative method, median FT3 Roche concentration was 10.5pmol/L (range <1.9 to >39.2), median FT3 concentration with alternative methods was 6.3pmol/L (range 3.9–9.6). 51-sample set: 27 FT3 measured with two methods, median FT3 Roche concentration was 8.4pmol/L (range 5.4–14.9), median FT3 with alternative methods was 5.9pmol/L (range 2.5–7.5).

Article Snippet: Dissociation enhanced lanthanide fluorescence immunoassay (DELFIA, Perkin Elmer) was used for the determination of serum TSH (reference range, RR: 0.5–3.6 mIU/L), FT4 (RR: 8.0–21.0 pmol/L) and until February 2016 for determination of FT3 (RR: 3.5–8.3 pmol/L).

Techniques: Comparison, Concentration Assay